Drug
Tizetatug rezetecan clinical trials
Keep track of what changes. Save the tizetatug rezetecan studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
Combined with it in one product
Studies by the year they started
10 studies that test it; most in 2024 (6)
| Year | Studies |
|---|---|
| 2021 | 1 |
| 2022 | 2 |
| 2023 | 1 |
| 2024 | 6 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 2 · Other 8
Fudan University (6) · Suzhou Suncadia Biopharmaceuticals Co., Ltd. (2) · Shanghai Pulmonary Hospital, Shanghai, China (1) · Henan Cancer Hospital (1)
Often tested with
Tested in the same studies.
Trastuzumab rezetecan (4) · Adebrelimab (3) · Ruzaltatug rezetecan (3) · Famitinib (3) · Bevacizumab (2) · Notiretatug rezetecan (2) · Trastuzumab (2) · Bulumtatug fuvedotin (2)
Studies
Open first, then newest update. How each study uses tizetatug rezetecan is read from its arms, and is right about nine times in ten.
Testing it · 10
- Platform Study of ADC Rechallenge in ADC-treated Metastatic Breast CancerRecruitingPhase 2Fudan UniversityNCT06649331Written as SHR-A1921
- Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant TherapyRecruitingPhase 2Fudan UniversityNCT05582499Written as SHR-A1921
- Study of SHR-A1921 Combined Adebrelimab in HR-positive, HER2-negative Advanced Breast CancerNot yet recruitingPhase 2Fudan UniversityNCT06470672Written as SHR-A1921
- SNF Platform Study of HR+/ HER2-advanced Breast CancerRecruitingPhase 2Fudan UniversityNCT05594095Written as SHR-A1921
- SHR-A1921 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian CancerRecruitingPhase 3Suzhou Suncadia Biopharmaceuticals Co., Ltd.NCT06394492Written as SHR-A1921
- SHR-A1921 Combined With Adebrelimab in the Treatment of Advanced NSCLC Who Failed the Previous Standard First-line TreatmentNot yet recruitingPhase 2Shanghai Pulmonary Hospital, Shanghai, ChinaNCT06480136Written as SHR-A1921 injection and adebrelimab injection
- Clinical Study of SHR-A1921 or SHR-A2009 in Previously Treated Advanced NSCLCNot yet recruitingPhase 2Henan Cancer HospitalNCT06465238Written as SHR-A1921
- SHR-A1921 Combined With Bevacizumab in Triple-negative Breast Cancer With Brain MetastasesNot yet recruitingPhase 2Fudan UniversityNCT06210438Written as SHR-A1921 + Bevacizumab
- A Phase II Study of Advanced Salivary Gland Carcinoma Based on Molecular TypingActive, not recruitingPhase 2Fudan UniversityNCT05924256Written as SHR-A1921
- A Study of SHR-A1921 for Injection in Subjects With Advanced Solid TumoursStatus unknownPhase 1Suzhou Suncadia Biopharmaceuticals Co., Ltd.NCT05154604Written as SHR-A1921
Given in every arm · 2 — tizetatug rezetecan is usual care beside what is tested
- Study of ADCs Combined With Adebrelimab in HER2-negative Advanced Breast CancerRecruitingPhase 2Beijing GoBroad HospitalNCT06433609Written as SHR-A1921
- A Phase IB/II Clinical Study of SHR-9839 for Injection Combined With Other Anti-tumor Therapies in Patients With Advanced Solid TumorsRecruitingPhase 1/2Shanghai Hengrui Pharmaceutical Co., Ltd.NCT06474455Written as SHR-A1921 for Injection
Codes
What other systems call tizetatug rezetecan · ClinicalTrials.gg INT018134
- UNII (FDA) UJR3SD8NLSTIZETATUG REZETECANOne source FDA
- NCI Thesaurus C211811Tizetatug RezetecanOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | UJR3SD8NLS | TIZETATUG REZETECAN | One source FDA |
| NCI Thesaurus | C211811 | Tizetatug Rezetecan | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.